Logo image of IMCC

IM CANNABIS CORP (IMCC) Stock Fundamental Analysis

NASDAQ:IMCC - Nasdaq - CA44969Q4060 - Common Stock - Currency: USD

1.91  +0.15 (+8.52%)

After market: 1.91 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to IMCC. IMCC was compared to 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of IMCC have multiple concerns. IMCC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IMCC has reported negative net income.
IMCC had a negative operating cash flow in the past year.
In the past 5 years IMCC always reported negative net income.
IMCC had a negative operating cash flow in each of the past 5 years.
IMCC Yearly Net Income VS EBIT VS OCF VS FCFIMCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of IMCC (-27.01%) is comparable to the rest of the industry.
The Return On Equity of IMCC (-201.89%) is worse than 67.17% of its industry peers.
Industry RankSector Rank
ROA -27.01%
ROE -201.89%
ROIC N/A
ROA(3y)-119.26%
ROA(5y)-87.85%
ROE(3y)-367.14%
ROE(5y)-273.77%
ROIC(3y)N/A
ROIC(5y)N/A
IMCC Yearly ROA, ROE, ROICIMCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

IMCC's Gross Margin of 15.64% is in line compared to the rest of the industry. IMCC outperforms 50.00% of its industry peers.
IMCC's Gross Margin has improved in the last couple of years.
IMCC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 15.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y497.26%
GM growth 5YN/A
IMCC Yearly Profit, Operating, Gross MarginsIMCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

0

2. Health

2.1 Basic Checks

IMCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IMCC has been increased compared to 1 year ago.
IMCC has more shares outstanding than it did 5 years ago.
The debt/assets ratio for IMCC is higher compared to a year ago.
IMCC Yearly Shares OutstandingIMCC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
IMCC Yearly Total Debt VS Total AssetsIMCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -8.67, we must say that IMCC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IMCC (-8.67) is worse than 69.19% of its industry peers.
IMCC has a Debt/Equity ratio of 3.01. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of IMCC (3.01) is worse than 78.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.01
Debt/FCF N/A
Altman-Z -8.67
ROIC/WACCN/A
WACC11.55%
IMCC Yearly LT Debt VS Equity VS FCFIMCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 0.67 indicates that IMCC may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.67, IMCC is doing worse than 89.39% of the companies in the same industry.
A Quick Ratio of 0.58 indicates that IMCC may have some problems paying its short term obligations.
The Quick ratio of IMCC (0.58) is worse than 87.37% of its industry peers.
Industry RankSector Rank
Current Ratio 0.67
Quick Ratio 0.58
IMCC Yearly Current Assets VS Current LiabilitesIMCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

IMCC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -78.84%.
IMCC shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.71%.
Measured over the past years, IMCC shows a quite strong growth in Revenue. The Revenue has been growing by 16.64% on average per year.
EPS 1Y (TTM)-78.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.33%
Revenue 1Y (TTM)10.71%
Revenue growth 3Y16.64%
Revenue growth 5YN/A
Sales Q2Q%24.65%

3.2 Future

Based on estimates for the next years, IMCC will show a very strong growth in Earnings Per Share. The EPS will grow by 36.54% on average per year.
The Revenue is expected to grow by 26.24% on average over the next years. This is a very strong growth
EPS Next Y86.24%
EPS Next 2Y36.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year41.23%
Revenue Next 2Y26.24%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IMCC Yearly Revenue VS EstimatesIMCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
IMCC Yearly EPS VS EstimatesIMCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -50 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

IMCC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMCC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMCC Price Earnings VS Forward Price EarningsIMCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMCC Per share dataIMCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

IMCC's earnings are expected to grow with 36.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.54%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMCC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IM CANNABIS CORP

NASDAQ:IMCC (5/23/2025, 8:25:09 PM)

After market: 1.91 0 (0%)

1.91

+0.15 (+8.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-15 2025-05-15
Earnings (Next)08-12 2025-08-12
Inst Owners3.91%
Inst Owner Change-1.12%
Ins Owners39.79%
Ins Owner ChangeN/A
Market Cap5.90M
Analysts82.86
Price TargetN/A
Short Float %1.11%
Short Ratio2.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)65.81%
Min EPS beat(2)60.06%
Max EPS beat(2)71.55%
EPS beat(4)3
Avg EPS beat(4)26.63%
Min EPS beat(4)-105.88%
Max EPS beat(4)80.78%
EPS beat(8)5
Avg EPS beat(8)-5.49%
EPS beat(12)5
Avg EPS beat(12)-392.42%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-11.24%
Min Revenue beat(2)-12.75%
Max Revenue beat(2)-9.73%
Revenue beat(4)2
Avg Revenue beat(4)-0.25%
Min Revenue beat(4)-12.75%
Max Revenue beat(4)11.57%
Revenue beat(8)3
Avg Revenue beat(8)-2.44%
Revenue beat(12)3
Avg Revenue beat(12)-8.36%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.15
P/FCF N/A
P/OCF N/A
P/B 1.56
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.44
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS12.64
BVpS1.23
TBVpS-1.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.01%
ROE -201.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 15.64%
FCFM N/A
ROA(3y)-119.26%
ROA(5y)-87.85%
ROE(3y)-367.14%
ROE(5y)-273.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y497.26%
GM growth 5YN/A
F-Score3
Asset Turnover1.38
Health
Industry RankSector Rank
Debt/Equity 3.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.14%
Cap/Sales 0.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.67
Quick Ratio 0.58
Altman-Z -8.67
F-Score3
WACC11.55%
ROIC/WACCN/A
Cap/Depr(3y)15.95%
Cap/Depr(5y)83.89%
Cap/Sales(3y)1.45%
Cap/Sales(5y)6.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-78.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.33%
EPS Next Y86.24%
EPS Next 2Y36.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)10.71%
Revenue growth 3Y16.64%
Revenue growth 5YN/A
Sales Q2Q%24.65%
Revenue Next Year41.23%
Revenue Next 2Y26.24%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y42.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year130.87%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y85.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.66%
OCF growth 3YN/A
OCF growth 5YN/A